Regeneron Pharmaceuticals looks cheaper than its cash flow may justify. A 2 Stage Free Cash Flow to Equity model valued the company at about $1,991.55 a share, far above a recent price of around $766, putting Regeneron stock at about 61.5% undervalued.
The model is built on a latest twelve month free cash flow figure of about $3.94 billion and projects that amount rising to about $5.05 billion in 2026, $8.38 billion in 2030 and $11.02 billion by 2035. For a company that returned 28.4% over the last year, the gap between price and modeled value is the central reason investors are paying attention today.
The valuation also matters because it gives a second look at how the market is pricing Regeneron against its peers. The stock currently trades at a P/E of 17.45x, the same as the broader Biotechs industry average and below the peer average of 23.30x, while Simply Wall St's Fair Ratio puts a fair multiple at 25.21x. That leaves Regeneron priced below both a peer benchmark and a proprietary estimate that tries to account for the company's growth profile.
That said, the numbers come from a model, not a guarantee. A 2 Stage Free Cash Flow to Equity approach leans on assumptions about future growth, and the farther out the forecast goes, the more those assumptions matter. The framework points to strong cash generation ahead, but it does not remove the risk that the market or the business may not follow the projected path.
For now, the stock's appeal rests on a straightforward mismatch: a company already producing billions in free cash flow, a valuation model that sees that cash expanding sharply over the next decade, and a share price that still sits well below the estimate. Investors deciding whether Regeneron belongs in their portfolio are really deciding how much faith to place in that future.
